Staidson Beijing Biopharma Tangible Net Worth Ratio
Staidson Beijing Biopharma tangible net worth ratio. Staidson Beijing Biopharma (300204) has a Tangible Net Worth Ratio of 70.2% as of March 2026. This metric is calculated by deducting intangible assets (CN¥236.85 Million) from net assets (CN¥794.92 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore Staidson Beijing Biopharma (300204) equity growth momentum to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Tangible Net Worth Ratio of Staidson Beijing Biopharma (2007–2025)
Tangible net worth ratio of Staidson Beijing Biopharma from 2007 to 2025. This chart shows how Staidson Beijing Biopharma's Tangible Net Worth Ratio has changed across 19 annual periods from 2007 to 2025. As of March 2026, the ratio stands at 70.2%, reflecting net assets of CN¥794.92 Million with intangible assets of CN¥236.85 Million CNY. Check Staidson Beijing Biopharma (300204) strategic asset index to assess the company's strategic physical and investment asset allocation.
Staidson Beijing Biopharma Tangible Net Worth Ratio by Year (2007–2025)
Staidson Beijing Biopharma tangible net worth ratio by year from 2007 to 2025. The table below presents the year-by-year Tangible Net Worth Ratio for Staidson Beijing Biopharma from 2007 to 2025, covering 19 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see Staidson Beijing Biopharma market cap and net worth.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 72.4% | CN¥806.72 Million | CN¥222.33 Million | CN¥1.27 Billion | ▼ -10.9 pp |
| 2024 | 83.4% | CN¥916.76 Million | CN¥152.34 Million | CN¥1.15 Billion | ▼ -7.1 pp |
| 2023 | 90.4% | CN¥1.02 Billion | CN¥97.62 Million | CN¥1.33 Billion | ▼ -1.6 pp |
| 2022 | 92.1% | CN¥1.35 Billion | CN¥107.22 Million | CN¥1.67 Billion | ▼ -2.3 pp |
| 2021 | 94.4% | CN¥1.55 Billion | CN¥87.34 Million | CN¥1.83 Billion | ▲ +0.9 pp |
| 2020 | 93.5% | CN¥1.59 Billion | CN¥103.10 Million | CN¥1.86 Billion | ▼ -3.4 pp |
| 2019 | 96.9% | CN¥1.64 Billion | CN¥50.34 Million | CN¥1.86 Billion | ▼ -1.3 pp |
| 2018 | 98.2% | CN¥2.46 Billion | CN¥44.70 Million | CN¥2.77 Billion | ▼ -0.2 pp |
| 2017 | 98.3% | CN¥2.21 Billion | CN¥36.47 Million | CN¥2.63 Billion | ▲ +0.3 pp |
| 2016 | 98.1% | CN¥1.92 Billion | CN¥36.93 Million | CN¥2.35 Billion | ▲ +0.3 pp |
| 2015 | 97.8% | CN¥1.68 Billion | CN¥37.39 Million | CN¥2.07 Billion | ▲ +1.9 pp |
| 2014 | 95.9% | CN¥1.51 Billion | CN¥62.17 Million | CN¥1.81 Billion | ▲ +0.7 pp |
| 2013 | 95.2% | CN¥1.31 Billion | CN¥62.61 Million | CN¥1.57 Billion | ▲ +0.4 pp |
| 2012 | 94.9% | CN¥1.24 Billion | CN¥63.65 Million | CN¥1.43 Billion | ▼ -3.0 pp |
| 2011 | 97.9% | CN¥1.10 Billion | CN¥23.52 Million | CN¥1.15 Billion | ▲ +14.1 pp |
| 2010 | 83.7% | CN¥166.23 Million | CN¥27.06 Million | CN¥264.88 Million | ▲ +7.4 pp |
| 2009 | 76.3% | CN¥119.72 Million | CN¥28.34 Million | CN¥148.75 Million | ▲ +26.2 pp |
| 2008 | 50.1% | CN¥62.82 Million | CN¥31.33 Million | CN¥92.07 Million | ▲ +8.8 pp |
| 2007 | 41.4% | CN¥33.87 Million | CN¥19.86 Million | CN¥82.22 Million | — |